Methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate, 95.0%, 5g

4H-Dibenzo[de,g]quinoline-1,9-diol, 5,6,6a,7-tetrahydro-2,10-dimethoxy-, (6aS)-, 98%, 250mg

(R)-tert-Butyl 3-formylpiperidine-1-carboxylate, 95.0%, 1g

5-Fluoro-2-(trifluoromethyl)cinnamic acid, 1g

3-(ethoxycarbonyl)-1-(2-ethylphenyl)-5-methyl-4,5-dihydro-1H-pyrazole-5-carboxylic acid, 95.0%, 2g

4-Ethyl-1-octyn-3-ol>97.0%(GC)500mL

(ISOQUINOLIN-8-YL)METHANOL, 95.0%, 1g

Pomalidomide-PEG1-C2-N3, 25mg

6-Bromofuro[2,3-d]pyrimidin-4-amine, 98%, 100mg

Objectif IOS plan PL S40x/0,65 corrigé à l'infini. Distance de travail 0,36 mm

(2E)-3-(2,5-dimethoxyphenyl)-1-(4-fluorophenyl)prop-2-en-1-one, 95.0%, 10g

Poudre de cuivre 99,8% -250 microns 1 g

1-Hexyl-3-methylimidazolium Iodide>98.0%(HPLC)25g